<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595709</url>
  </required_header>
  <id_info>
    <org_study_id>YJ14001-COMBO-201801</org_study_id>
    <nct_id>NCT03595709</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan</brief_title>
  <official_title>Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF, Emtricitabine and Efavirenz (Atripla) With Viral Suppression in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yu-Jay Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yu-Jay Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus
      Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo)
      for Patients Receiving Co-Formulated TDF, Emtricitabine and Efavirenz (Atripla) with Viral
      Suppression in Taiwan
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efavirenz (EFV) is the most widely used non-nucleoside reverse transcriptase inhibitor
      (NNRTI). The recommended dose of EFV is 600 mg daily; however, a phase II study showed no
      significant difference in viral suppression rates across the different EFV groups (200 mg,
      400 mg, and 600 mg) at 24 weeks. The week 96 analysis of ENCORE 1 study confirmed the durable
      virological non-inferiority of EFV 400 mg to the standard 600 mg dose when given as initial
      therapy with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Fewer EFV-related
      adverse events (AEs) and fewer treatment discontinuations were also observed in the reduced
      dose group. The efficacy and safety findings provide robust evidence to redefine the EFV dose
      for HIV treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 6, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-arm, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C12 EFV concentration</measure>
    <time_frame>Week 4</time_frame>
    <description>The proportion of subjects achieving C12 EFV concentration &gt;1.0 mg/L at Week 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA load</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects with undetectable plasma HIV-1 RNA load (&lt;50 copies/mL) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA load</measure>
    <time_frame>Week 24</time_frame>
    <description>The proportion of subjects with undetectable plasma HIV-1 RNA load (&lt;50 copies/mL) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFV concentration</measure>
    <time_frame>Week 4</time_frame>
    <description>The mean changes from baseline in C12 EFV concentration at Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell count</measure>
    <time_frame>Week 12</time_frame>
    <description>The mean changes from baseline in CD4+ T cell count at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell count</measure>
    <time_frame>Week 24</time_frame>
    <description>The mean changes from baseline in CD4+ T cell count at Week 24.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>combined tablet (EFV 400,TDF 300, 3TC 300)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)</intervention_name>
    <description>All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.</description>
    <arm_group_label>combined tablet (EFV 400,TDF 300, 3TC 300)</arm_group_label>
    <other_name>non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are receiving co-formulated TDF/ FTC/ EFV (600 mg) and have achieved an
             undetectable plasma viral load (&lt;50 copies/mL) for 6 months or longer at screening
             visit.

          -  Having C12 EFV of 1 mg/L or greater at screening.

          -  (C12 EFV will be determined by using blood sample collected 12 ± 1 hour after previous
             dosing of co-formulated TDF/ FTC/ EFV (600 mg).

          -  No known treatment failure to regimens containing TDF, 3TC or FTC, plus EFV.

          -  Infected with HIV harboring no known resistance-associated mutations to EFV, TDF, 3TC
             or FTC.

          -  No known allergies to EFV, TDF, 3TC or FTC.

          -  Aged ≧20 years.

          -  Calculated creatinine clearance (ClCr) ≥ 50 mL/min (Cockcroft-Gault formula).

          -  Provision of written informed consent.

        Exclusion Criteria:

          -  The following laboratory values:

               -  Absolute neutrophil count (ANC) &lt;500 cells/μL

               -  Hemoglobin &lt;7.0 g/dL

               -  Platelet count &lt;50,000 cells/μL

               -  Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
                  levels &gt;5x upper limit of normal (ULN)

          -  Pregnant women or nursing mothers.

          -  Active opportunistic or malignant disease not under adequate control.

          -  Use of immunomodulators within 30 days prior to screening visit.

          -  Use any of the prohibited medications: bepridil, astemizole, terfenadine,
             dihydroergotamine, ergometrine, ergotamine, systemic cytotoxic chemotherapy,
             amodiaquine, pimozide, midazolam, triazolam, cisapride、St John's Wort、
             Elbasvir/Grazoprevir and Simeprevir.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsin-Yun Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efavirenz</keyword>
  <keyword>HIV Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

